Jacob “Jake” Leach, President/CEO of Dexcom, has been appointed as the new chair of the AdvaMed Diabetes Sector, succeeding Chris Scoggins of Abbott. In this role, he will lead efforts to advocate for policies that expand access to diabetes technologies and improve patient outcomes. Leach brings over two decades of experience from Dexcom, where he significantly contributed to the company’s growth and its mission to advance patient-centered diabetes care.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dexcom’s CEO to Chair AdvaMed’s Diabetes Sector
Jacob “Jake” Leach, President/CEO of Dexcom, has been appointed as the new chair of the AdvaMed Diabetes Sector, succeeding Chris Scoggins of Abbott. In this role, he will lead efforts to advocate for policies that expand access to diabetes technologies and improve patient outcomes. Leach brings over two decades of experience from Dexcom, where he significantly contributed to the company’s growth and its mission to advance patient-centered diabetes care.